IRIS
LAMBERTINI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 22.686
AS - Asia 3.753
NA - Nord America 3.709
Continente sconosciuto - Info sul continente non disponibili 1.070
SA - Sud America 335
AF - Africa 67
OC - Oceania 7
Totale 31.627
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 21.765
US - Stati Uniti d'America 3.481
SG - Singapore 1.387
CN - Cina 961
VN - Vietnam 527
BD - Bangladesh 489
FI - Finlandia 305
FR - Francia 294
BR - Brasile 201
HK - Hong Kong 133
DE - Germania 113
CA - Canada 88
MX - Messico 51
AR - Argentina 49
JP - Giappone 45
GB - Regno Unito 42
IN - India 33
NL - Olanda 29
EC - Ecuador 25
ID - Indonesia 23
ES - Italia 22
JM - Giamaica 20
IQ - Iraq 19
RU - Federazione Russa 19
CH - Svizzera 18
CR - Costa Rica 15
ZA - Sudafrica 15
CO - Colombia 14
PH - Filippine 14
PY - Paraguay 14
AT - Austria 13
MY - Malesia 13
CL - Cile 12
IE - Irlanda 12
UA - Ucraina 12
UZ - Uzbekistan 12
PK - Pakistan 11
GT - Guatemala 9
HN - Honduras 9
KE - Kenya 9
SA - Arabia Saudita 9
VE - Venezuela 9
JO - Giordania 8
KR - Corea 8
MA - Marocco 8
TR - Turchia 8
DZ - Algeria 7
TW - Taiwan 7
AU - Australia 6
BE - Belgio 6
KW - Kuwait 6
SE - Svezia 6
SV - El Salvador 6
TH - Thailandia 6
NI - Nicaragua 5
NP - Nepal 5
TN - Tunisia 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
DO - Repubblica Dominicana 4
PR - Porto Rico 4
SC - Seychelles 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AM - Armenia 3
BB - Barbados 3
BO - Bolivia 3
BS - Bahamas 3
CZ - Repubblica Ceca 3
EG - Egitto 3
IL - Israele 3
IR - Iran 3
KZ - Kazakistan 3
LB - Libano 3
PE - Perù 3
PL - Polonia 3
RO - Romania 3
SI - Slovenia 3
UY - Uruguay 3
BY - Bielorussia 2
CG - Congo 2
CI - Costa d'Avorio 2
CU - Cuba 2
GA - Gabon 2
GR - Grecia 2
LY - Libia 2
MR - Mauritania 2
PT - Portogallo 2
RS - Serbia 2
SY - Repubblica araba siriana 2
BF - Burkina Faso 1
BG - Bulgaria 1
BM - Bermuda 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
CD - Congo 1
CY - Cipro 1
GF - Guiana Francese 1
GN - Guinea 1
GP - Guadalupe 1
KH - Cambogia 1
Totale 30.542
Salva come PNG Salva come JPEG
Città #
Genova 9.523
Genoa 8.286
Vado Ligure 1.817
Rapallo 1.564
San Jose 691
Singapore 608
Ashburn 568
Helsinki 284
Council Bluffs 280
Lauterbourg 261
Beijing 160
Ho Chi Minh City 154
New York 154
Hong Kong 128
Hanoi 123
Santa Clara 103
Bordighera 74
Los Angeles 63
Frankfurt am Main 62
Boardman 50
Milan 43
St Louis 43
Buffalo 40
Dallas 34
Tokyo 34
Chicago 33
Naples 33
Rome 31
Mexico City 30
Haiphong 27
Tianjin 27
Da Nang 25
São Paulo 24
Atlanta 23
Schiffdorf 23
Orem 21
Lappeenranta 20
Miami 18
Columbus 17
Houston 17
Philadelphia 17
Amsterdam 16
Zurich 15
Bologna 14
Brooklyn 14
Guangzhou 14
Phoenix 14
San José 14
Toronto 14
Kingston 13
Orlando 13
Seattle 13
Dublin 12
Palermo 12
Tashkent 12
Montreal 11
Newark 11
City of London 10
Curitiba 10
Quito 10
Asunción 9
Bari 9
Boston 9
Louisville 9
Shanghai 9
Vienna 9
Agawam 8
Brescia 8
Guatemala City 8
Hải Dương 8
Johannesburg 8
Padua 8
Shenzhen 8
The Bronx 8
Washington 8
Amman 7
Baghdad 7
Florence 7
Jacksonville 7
Madrid 7
Nairobi 7
Nashville 7
Phủ Lý 7
Pittsburgh 7
Princeton 7
Queens 7
San Antonio 7
Surrey 7
Thái Bình 7
Chengdu 6
Detroit 6
Fort Lauderdale 6
Kuala Lumpur 6
Kyiv 6
Lahore 6
Las Vegas 6
London 6
Paris 6
Richmond 6
Rio de Janeiro 6
Totale 26.065
Salva come PNG Salva come JPEG
Nome #
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis 241
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis 227
The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs) 226
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 207
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 207
Cancer and fertility preservation: international recommendations from an expert meeting 206
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies 205
State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature 197
Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies 197
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study 196
Management of young women with early breast cancer 192
Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence 189
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO) 188
Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate? 186
Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer 185
The PREgnancy and FERtility (PREFER) study: An Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients 179
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 179
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: Results of an observational study 179
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient–level data 178
Adverse events and impact on quality of life of antibody-drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta-analysis 177
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis 177
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 171
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients 169
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 168
Biology, staging, and treatment of breast cancer during pregnancy: reassessing the evidences 168
News on the medical treatment of young women with early-stage HER2-negative breast cancer 167
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 167
Adherence to guidelines in requesting oncotype DX in a publicly funded health care system 167
Treatment with aromatase inhibitors and markers of cardiovascular disease 166
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial 165
The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients 165
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 165
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials 163
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open-Cancer Horizons" Series 163
Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients 162
Beyond fertility preservation: role of the oncofertility unit in the reproductive and gynecological follow-up of young cancer patients 162
Pharmacotherapy to protect ovarian function and fertility during cancer treatment 160
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients 160
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis 157
Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients 156
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer 155
Exploring the safety of chemotherapy for treating breast cancer during pregnancy 155
Adjuvant trastuzumab: a 10-year overview of its benefit 153
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival A Randomized Clinical Trial 153
Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials 152
Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors? 151
Letrozole withdrawal response in locally advanced breast cancer 151
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 151
Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells 151
Safety and feasibility of fasting‐mimicking diet and effects on nutritional status and circulating metabolic and inflammatory factors in cancer patients undergoing active treatment 151
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients 150
Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy 150
Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting 149
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer 149
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 148
Ovarian suppression using luteinizing hormonereleasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: A meta-analysis of randomized studies 148
Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis 146
Fertility, sexuality and cancer in young adult women 146
Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy 145
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 144
Another step towards improving oncofertility counselling of young women with Hodgkin's lymphoma 144
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial 143
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients 142
Follow-up strategies for women treated for early breast cancer 142
Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial 142
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients 141
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial 141
Reply to the letter to the editor 'Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?' by Rodriguez-Wallberg et al. 140
Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients 140
Targeted agents for cancer treatment during pregnancy 139
Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy 139
Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer 139
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives 137
A pooled analysis of the cardiac events in the trastuzumab adjuvant trials 137
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis 136
Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects 136
Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology 135
Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations 135
Reply to the letter "Safety of fertility preservation in women with breast cancer" 135
Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients 134
Implementing the hub and spoke model for the oncofertility units 133
Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial 132
Tumor-to-nipple Distance Should Not Preclude Nipple-sparing Mastectomy in Breast Cancer Patients. Personal Experience and Literature Review 132
Comparing the gonadotoxicity of multiple breast cancer regimens: Important understanding for managing breast cancer in pre-menopausal women 132
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate 132
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 131
What medical oncologist residents think about the Italian speciality schools: A survey of the Italian Association of Medical Oncology (AIOM) on educational, clinical and research activities 131
Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors 130
Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do? 130
Long-term safety of pregnancy following breast cancer according to estrogen receptor status 129
Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer 129
Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities 129
Approaches to Fertility Preservation for Young Women With Breast Cancer 128
Triple-negative breast cancer: Current perspective on the evolving therapeutic landscape 128
Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers 128
How I treat metastatic triple-negative breast cancer 126
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial 125
Current practices in oncofertility counseling: updated evidence on fertility preservation and post-treatment pregnancies in young women affected by early breast cancer 125
The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer 124
Radiation therapy for young women with early breast cancer: Current state of the art 122
Totale 15.590
Salva come PNG Salva come JPEG
Categoria #
all - tutte 119.043
article - articoli 118.600
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 443
Totale 238.086
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.453 166 82 108 237 58 230 82 523 278 259 98 332
2022/20232.027 265 194 38 162 269 260 53 186 376 16 186 22
2023/20241.623 53 153 38 198 111 143 93 112 87 113 135 387
2024/20254.968 141 376 97 278 671 541 525 768 242 250 490 589
2025/202611.950 1.011 471 1.365 962 1.217 922 1.668 569 840 1.176 750 999
2026/2027936 936 0 0 0 0 0 0 0 0 0 0 0
Totale 31.627